Exciting trials at SABCS 2021 for pre- vs. post-menopausal hormone receptor-positive breast cancer

• Date :
• 4    
  0

Treatment algorithm for TNBC

• Date :
• 4    
  0

Standard of care for patients with breast cancer who develop brain metastases

• Date :
• 3    
  0

Managing breast cancer in young patients

• Date :
• 2    
  0

Adjuvant/neoadjuvant therapy trials for breast cancer at SABCS 2021

• Date :
• 1    
  0

FLEX: real-world data platform bringing precision medicine to the clinic

• Date :
• 1    
  0

Late and long-lasting effects of cancer treatment

• Date :
• 1    
  0

Molecular heterogeneity in HER2+ breast cancer and predicting outcomes

• Date :
• 0    
  0

Impact of genomic testing on treatment decision-making in breast cancer

• Date :
• 0    
  0

Final results from PALLAS: adjuvant palbociclib in HR+/HER2- early breast cancer

• Date :
• 0    
  0

16-gene signature identifies early-stage invasive breast cancer patients who may omit radiotherapy

• Date :
• 0    
  0

Advances in the management of inflammatory breast cancer

• Date :
• 0    
  0

Quality of life results from OlympiA

• Date :
• 0    
  0

Predicted sensitivity to ET (SET2,3 index): results of an analysis of the SWOG S8814 trial

• Date :
• 0    
  0

How to tell when basic science discoveries are ready to translate?

• Date :
• 0    
  0

KEYNOTE-522: EFS sensitivity & subgroup analyses

• Date :
• 0    
  0

Single-cell spatial analysis in TNBC from NeoTRIPaPDL1

• Date :
• 0    
  0

Genome-wide ctDNA assessment predicts outcome and resistance in HR+/HER2- MBC treated with CDK4/6i

• Date :
• 0    
  0

Improving access to therapies for breast cancer patients

• Date :
• 0    
  0

Recent breast cancer updates from SABCS 2021

• Date :
• 0    
  0

Racial differences in the breast tumor microenvironment

• Date :
• 0    
  0

How useful are checkpoint inhibitors in the treatment of breast cancer?

• Date :
• 0    
  0

Highlights from SABCS 2021

• Date :
• 0    
  0

Future research directions for ER+ positive breast cancer

• Date :
• 0    
  0

AMEERA-5: amcenestrant + palbociclib for previously untreated ER+/HER2- advanced breast cancer

• Date :
• 0    
  0

TROPION-PanTumor01: datopotamab deruxtecan in advanced HER2+ breast cancer

• Date :
• 0    
  0

Samuraciclib in combination with fulvestrant in patients with advanced HR+/HER2- breast cancer

• Date :
• 0    
  0

ALTERNATE: neoadjuvant endocrine treatment in ER+/HER2- breast cancer

• Date :
• 0    
  0

REACT: effect of celecoxib vs placebo as adjuvant therapy on DFS among patients with breast cancer

• Date :
• 0    
  0

Disparities in the practice of precision medicine

• Date :
• 0    
  0

Predictive biomarkers in breast cancer

• Date :
• 0    
  0

What are you looking forward to at SABCS 2021?

• Date :
• 0    
  0

12-year follow-up of SOFT and TEXT trials

• Date :
• 0    
  0

EMERALD: elacestrant vs. SOC for patients with ER+ HER2- metastatic breast cancer

• Date :
• 0    
  0

Impact of COVID-19 on clinical practice in radiation therapy

• Date :
• 0    
  0

Congrès ESMO 2026

• Date :
• 7337    
  0

17ème Biennale Monégasque de Cancérologie

• Date :
• 902    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date :
• 7591    
  0

SABCS 2025 Symposium

• Date :
• 17414    
  0

Congrès ESMO Asie 2025

• Date :
• 5866    
  0